Already a well-established treatment for different autonomic and movement disorders, the
use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding …

Botulinum neurotoxin (BoNT), derived from Clostridium botulinum, has been used
therapeutically for focal dystonia, spasticity, and chronic migraine. Its spectrum as a potential …

Botulinum neurotoxin type A (BoNT/A) is one of the most potent toxins known and a potential
biological threat. At the same time, it is among the most widely used therapeutic proteins …

The antinociceptive effect of BoNT-A have been well documented in animal studies;
however, results of few but well-designed randomized placebo-controlled clinical trials …

This study assessed the long-term effects of botulinum toxin type A (BoNT-A) in subjective
pain, pain sensibility, and muscle thickness in persistent myofascial temporomandibular …

Botulinum neurotoxin A (BoNT/A) is a toxin produced by the naturally-occurring Clostridium
botulinum that causes botulism. The potential of BoNT/A as a useful medical intervention …

Botulinum toxin serotype A (Bo NT/A) was originally used in neurology for the treatment of
dystonia and blepharospasms, but is now clinically used worldwide for the treatment of …

The antinociceptive action of botulinum toxin type A (BoNT/A) has been demonstrated in
behavioral animal studies and clinical settings. It was shown that this effect is associated …

(1) Background: OnabotulinumtoxinA (BoNT-A) is a commonly used prophylactic treatment
for chronic migraine (CM). Although randomized placebo studies have shown its clinical …

We addressed the hypothesis that intraplantar botulinum toxin B (rimabotulinumtoxin B:
BoNT-B) has an early local effect upon peripheral afferent terminal releasing function and …